ReviewNature reviews. Urology2012
Patented prostate cancer biomarkers.
Review in Nature reviews. Urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gene Expression Studies to Identify Significant Genes in AR, MTOR, MAPK Pathways and their Overlapping Regulatory Role in Prostate Cancer.Journal of integrative bioinformatics · 2019Pooled it
- METCAM Is a Potential Biomarker for Predicting the Malignant Propensity of and as a Therapeutic Target for Prostate Cancer.Biomedicines · 2023Review
- Validating METCAM/MUC18 as a Novel Biomarker to Predict the Malignant Potential of Prostate Cancer at an Early Stage by Using a Modified Gold Nanoparticles-Based Lateral Flow Immunoassay.Diagnostics (Basel, Switzerland) · 2021Article
- METCAM/MUC18 is a new early diagnostic biomarker for the malignant potential of prostate cancer: Validation with Western blot method, enzyme-linked immunosorbent assay and lateral flow immunoassay.Cancer biomarkers : section A of Disease markers · 2020Article
- Focal Ablation of Prostate Cancer.Reviews in urology · 2018Article
- Oxidative stress markers in prostate cancer patients after HDR brachytherapy combined with external beam radiation.Oxidative medicine and cellular longevity · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most frequently diagnosed cancer in men. However, current diagnostic techniques (including serum PSA level measurement) lack sufficient specificity and sensitivity to determine the aggressiveness of the disease and to identify appropriate treatment. Additional reliable biomarkers are needed that can facilitate early diagnosis of prostate cancer, determine the patient's prognosis and predict responses to a given therapeutic intervention. To achieve clinical utility, biomarkers require the potential for commercialization, and such an investment is generally only made if a financial return is promised. Patenting is one way to protect the intellectual property surrounding such biomarkers and several patented biomarkers are being developed, although few have been validated in large-scale clinical trials.
Indexed as
Identifiers
22750955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.